Luminopia's amblyopia treatment now includes patients aged 8 to 12, expanding its previous FDA approval for ages 4 to 7. The ...

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Shehzad Batliwala, DO, known to his patients as Dr. Shehz, appeared on the ASCRS Foundation Symposium, where he discussed ...

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative ...

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient ...

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration ...

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of ...

Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 ...